AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

SubscribeContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

13 Apr
AHFS Drug Information logo
AHFS April 2021 Update

This update contains 8 new monographs and 4 revised monographs.

New monographs: Remimazolam; Margetuximab-Cmkb; Cabotegravir Sodium; Cabotegravir And Rilpivirine; Voclosporin; Abametapir; Collagenase Clostridium Histolyticum-Aaes; Vericiguat

Revised monographs: Abatacept; COVID-19 Vaccine (Pfizer-BioNTech); COVID-19 Vaccine (Moderna); Immune Globulin

09 Mar
AHFS Drug Information logo
AHFS March 2021 Update

This update contains 9 new monographs and 13 revised monographs.

New monographs: Setmelanotide; Tirbanibulin; Lonafarnib; Ansuvimab-zykl; Vibegron; COVID-19 Vaccine (Pfizer-BioNTech); COVID-19 Vaccine (Moderna); Relugolix; Naxitamab-gqgk

Revised monographs: Triptorelin; HMG-CoA Reductase Inhibitors General Statement; Goserelin; Adalimumab; Mycophenolate; Crizotinib; Ceritinib; Alectinib; Tamoxifen; Leuprolide; Anastrozole; Letrozole; Exemestane

09 Feb
AHFS Drug Information logo
AHFS February 2021 Update

This update contains 3 new monographs and 7 revised monographs.

New monographs: Lumasiran Sodium; Berotralstat; Oliceridine Fumarate

Revised monographs: Montelukast; Brinzolamide; Brimonidine; Phentermine and Topiramate; Timolol; Betaxolol; Dorzolamide

12 Jan
AHFS Drug Information logo
AHFS January 2021 Update

This update contains 3 new monographs, 53 revised monographs and 33 new MedWatch alerts.

New monographs: Atoltivimab, Maftivimab, and Odesivimab-ebgn; Bamlanivimab; Casirivimab and Imdevimab

Revised monographs: Rivastigmine; Meloxicam; Galantamine; Travoprost; Flurbiprofen; Pregabalin; CloBAZam; Ibrutinib; Netarsudil Mesylate; Ivosidenib; Stiripentol; Solriamfetol; Pitolisant; Enfortumab Vedotin-ejfv; Fam-Trastuzumab Deruxtecan-nxki; Fenoprofen; Indomethacin; Mefenamic Acid; Naproxen; Tolmetin; Sulindac; DiazePAM; Oxazepam; Flurazepam; Clorazepate; LORazepam; ChlordiazePOXIDE; Ibuprofen; ClonazePAM; Meclofenamate; Valproate/Divalproex; Aspirin; Anticonvulsants General Statement; Carbonic Anhydrase Inhibitors General Statement; ALPRAZolam; Temazepam; Triazolam; Diflunisal; Piroxicam; Levobunolol; Ketoprofen; Diclofenac; Ketorolac; Quazepam; CloZAPine; Estazolam; Etodolac; Nabumetone; Oxaprozin; Gabapentin; Topiramate; Donepezil; Celecoxib

New MedWatch alerts on the following monographs: Meloxicam; Flurbiprofen; Fenoprofen; Indomethacin; Mefenamic Acid; Naproxen; Tolmetin; Sulindac; Ibuprofen; Meclofenamate; Aspirin; Diflunisal; Piroxicam; Ketoprofen; Diclofenac; Ketorolac; Etodolac; Nabumetone; Oxaprozin; Celecoxib; Clobazam; Diazepam; Oxazepam; Flurazepam; Clorazepate; Lorazepam; Chlordiazepoxide; Clonazepam; Alprazolam; Temazepam; Triazolam; Quazepam; Estazolam

08 Dec
AHFS Drug Information logo
AHFS December 2020 Update

This update contains 1 new monograph, 43 revised monographs and 1 discontinued monograph.

New monograph: Nifurtimox

Revised monographs: Mifepristone; Bimatoprost; Alemtuzumab (Antineoplastic); Memantine; Tolvaptan; Tafluprost; Dolutegravir; Idelalisib; Panobinostat; Parathyroid Hormone; Alemtuzumab (MS); Blinatumomab; Flibanserin; Latanoprostene bunod; Semaglutide; Pegvaliase-pqpz; Duvelisib; Inotersen; Revefenacin; Ravulizumab-cwvz; Ketamine; Esketamine; Brexanolone; Pexidartinib; Enfortumab Vedotin-ejfv; Tazemetostat; Remdesivir; Satralizumab-mwge; Levorphanol; Codeine; Meperidine; Oxymorphone; Morphine; Loxapine; Pentazocine; Hydrocodone; Butorphanol; Cathartics and Laxatives General Statement; Insulin Human; Tramadol; Latanoprost; Olanzapine; Thalidomide

Discontinued monograph: Delavirdine

10 Nov
AHFS Drug Information logo
AHFS November 2020 Update

This update contains 1 new monograph and 10 revised monographs.

New monograph: Pralsetinib

Revised monographs: Raltegravir Potassium; Ofatumumab (Antineoplastic); Tagraxofusp-erzs; Polatuzumab Vedotin-piiq; Zanubrutinib; Avapritinib; Remdesivir; Ofatumumab (Multiple Sclerosis); Opiate Agonists General Statement; Antiretroviral Agents General Statement

View more View all content updates